首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 再生醫學分子標靶治療學細胞療法基因療法

市場調查報告書

商品編碼

1490926

分子細胞遺傳學市場 - 按產品類型、技術、應用、最終用途 - 全球預測

Molecular Cytogenetics Market - By Product Type, Technology, Application, End-use - Global Forecast 2024 - 2032

出版日期: 2024年03月22日 | 出版商:

Global Market Insights Inc. | 英文 278 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於對精確檢測遺傳異常和染色體變異的先進診斷技術的需求不斷成長，預計 2024 年至 2032 年間，分子細胞遺傳學市場規模的複合年成長率將達到 10.1%。螢光原位雜合技術 (FISH) 和比較基因組雜交 (CGH) 等技術在識別與各種疾病（包括癌症和遺傳性疾病）相關的遺傳變異方面具有高靈敏度和特異性。全球遺傳性疾病和癌症的日益普及進一步推動了對分子細胞遺傳學技術的需求，以實現精確診斷、預後和治療計劃。根據世界衛生組織的數據，2022 年，約有 2,000 萬新發癌症病例，導致 970 萬人死亡。

分子細胞遺傳學平台的持續創新，例如下一代定序（NGS）和基於微陣列的技術，正在增強他們以更高的解析度和通量分析染色體異常和結構變異的能力。此外，分子細胞遺傳學與聚合酶鍊式反應（PCR）和基因表現分析等其他分子生物學技術的整合，可實現全面的基因組分析和疾病的分子表徵，這將促進市場成長。

分子細胞遺傳學產業分為產品類型、技術、應用、最終用途和地區。

根據產品類型，儀器儀表領域的市場價值預計將產生可觀的收入，到 2032 年複合年成長率為 9.9%。儀器提供的準確性、靈敏度和通量有利於這種成長，從而能夠有效、可靠地檢測染色體異常和遺傳變異。儀器技術的不斷進步，例如自動化、小型化和連接複用功能，也有助於簡化工作流程、減少週轉時間並提高資料質量，從而增加了它們在實驗室和研究設施中的吸引力。

在對精確檢測和表徵遺傳異常的先進診斷解決方案的需求的支持下，遺傳性疾病應用領域的分子細胞遺傳學行業預計在 2024 年至 2032 年期間將實現 9.9% 的成長率。分子細胞遺傳學領域正在進行的研究和技術進步正在進一步增強其識別新型遺傳標記和闡明遺傳疾病潛在機制的能力，從而促進該細分市場的成長。

亞太地區分子細胞遺傳學產業預計 2024 年至 2032 年複合年成長率為 10.4%。亞太地區人口不斷成長，遺傳性疾病盛行率不斷上升，導致對先進診斷技術的需求不斷成長，以滿足醫療保健需求。旨在提高醫療保健可近性和負擔能力的積極主動的政府舉措，加上不斷增加的研發投資，也將促進分子細胞遺傳學技術在該地區的採用。

產業生態系統分析
產業影響力
- 成長動力
  - 遺傳性疾病和癌症的盛行率不斷上升
  - 分子細胞遺傳學的技術進步
  - 個人化醫療的採用不斷增加
  - 擴大在研究和臨床診斷的應用
- 產業陷阱與挑戰
  - 嚴格的監管場景
  - 分子細胞遺傳學檢測成本高
成長潛力分析
技術景觀
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
競爭定位矩陣
戰略展望矩陣

第 5 章：市場估計與預測：按產品類型，2021 - 2032 年

主要趨勢
儀器
試劑和試劑盒
- 測試套件
- 探頭
- 螢光親和試劑
- 其他試劑和試劑盒
耗材
軟體與服務

第 6 章：市場估計與預測：按技術分類，2021 - 2032 年

主要趨勢
比較基因組雜交（CGH）
- 基於晶片的比較基因組雜交 (aCGH)
- 標準比較基因組雜交 (sCGH)
螢光原位雜合技術（FISH）
免疫組織化學
核型分析
- 光譜
- 虛擬的
其他技術

第 7 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
遺傳性疾病
腫瘤學
個人化醫療
其他應用

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
臨床和研究實驗室
學術研究機構
製藥和生物技術公司
其他最終用戶

第 9 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Abbott Laboratories
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
BioView Ltd.
Danaher Corporation
F. Hoffmann-La Roche Ltd.
Illumina, Inc.
MetaSystems
PerkinElmer, Inc.
Sysmex Corporation

簡介目錄

Product Code: 8693

Molecular cytogenetics market size is projected to record 10.1% CAGR between 2024 and 2032, driven by the increasing demand for advanced diagnostic techniques to accurately detect genetic abnormalities and chromosomal alterations. Techniques, such as fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH) offer high sensitivity and specificity in identifying genetic variations associated with various diseases, including cancer and genetic disorders. The growing prevalence of genetic disorders and cancer worldwide is further fueling the demand for molecular cytogenetics technologies for precise diagnosis, prognosis, and treatment planning. As per WHO, in 2022, there were approximately 20 million new cancer cases, resulting in 9.7 million deaths.

Continuous innovation in molecular cytogenetics platforms, such as next-generation sequencing (NGS) and microarray-based techniques is enhancing their capabilities in analyzing chromosomal abnormalities and structural variations at a higher resolution and throughput. Moreover, the integration of molecular cytogenetics with other molecular biology techniques like polymerase chain reaction (PCR) and gene expression analysis to enables comprehensive genomic profiling and molecular characterization of diseases will add to the market growth.

The molecular cytogenetics industry is classified into product type, technology, application, end-use and region.

Based on product type, the market value from the instruments segment is poised to generate substantial revenue, depicting a 9.9% CAGR through2032. The growth is favored by the accuracy, sensitivity, and throughput provided by instruments in enabling efficient and reliable detection of chromosomal abnormalities and genetic variations. Growing advancements in instrument technology, such as automation, miniaturization, and multiplexing capabilities also help streamline workflows, reduce turnaround times, and improve data quality, adding to their appeal in laboratories and research facilities.

Molecular cytogenetics industry from the genetic disorders application segment is slated to witness 9.9% growth rate during 2024-2032, backed by the demand for advanced diagnostic solutions to accurately detect and characterize genetic abnormalities. The ongoing research and technological advancements in molecular cytogenetics are further enhancing its capabilities in identifying novel genetic markers and elucidating the underlying mechanisms of genetic diseases, contributing to the segment growth.

Asia Pacific molecular cytogenetics industry is expected to grow at a 10.4% CAGR over 2024-2032. The expanding population and increasing prevalence of genetic disorders in APAC is contributing to the rising demand for advanced diagnostic technologies to address healthcare needs. The proactive government initiatives aimed at enhancing healthcare accessibility and affordability, coupled with the growing investments in R&D will also foster the adoption of molecular cytogenetics technologies in the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of genetic disorders and cancer
  - 3.2.1.2 Technological advancements in molecular cytogenetics
  - 3.2.1.3 Rising adoption of personalized medicine
  - 3.2.1.4 Expanding applications in research and clinical diagnostics
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory scenario
  - 3.2.2.2 High cost of molecular cytogenetic tests
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Instruments
5.3 Reagents and kits
- 5.3.1 Testing kits
- 5.3.2 Probes
- 5.3.3 Fluorescent affinity reagents
- 5.3.4 Other reagents and kits
5.4 Consumables
5.5 Software & services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Comparative genomic hybridization (CGH)
- 6.2.1 Array-based comparative genomic hybridization (aCGH)
- 6.2.2 Standard comparative genomic hybridization (sCGH)
6.3 Fluorescence in-situ hybridization (FISH)
6.4 Immunohistochemistry
6.5 Karyotyping
- 6.5.1 Spectral
- 6.5.2 Virtual
6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Genetic disorders
7.3 Oncology
7.4 Personalized medicine
7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Clinical & research laboratories
8.3 Academic research institutes
8.4 Pharmaceutical & biotech companies
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa